Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Accumulated Expenses (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Accumulated Expenses for 11 consecutive years, with $2.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Accumulated Expenses changed N/A year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Jun 2025, changed N/A, and an annual FY2024 reading of $4.6 million, up 232.35% over the prior year.
  • Accumulated Expenses was $2.5 million for Q2 2025 at Kiora Pharmaceuticals, down from $3.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.6 million in Q4 2024 and bottomed at $362736.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $1.8 million, with a median of $1.4 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses plummeted 43.06% in 2022, then skyrocketed 285.69% in 2023.
  • Year by year, Accumulated Expenses stood at $1.3 million in 2021, then tumbled by 72.73% to $362736.0 in 2022, then soared by 280.63% to $1.4 million in 2023, then surged by 232.35% to $4.6 million in 2024, then plummeted by 44.64% to $2.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for KPRX at $2.5 million in Q2 2025, $3.5 million in Q1 2025, and $4.6 million in Q4 2024.